Hladik Bernhard, Buscke Florence, Frost Robert, Rothhaar Uwe
SCHOTT Pharmaceutical Systems, SCHOTT AG, Hattenbergstrasse 10, 55122 Mainz, Germany; and
SCHOTT Pharmaceutical Systems, SCHOTT AG, Hattenbergstrasse 10, 55122 Mainz, Germany; and.
PDA J Pharm Sci Technol. 2019 Jul-Aug;73(4):345-355. doi: 10.5731/pdajpst.2018.009472. Epub 2019 Feb 15.
The pharmacopeia method for measuring the chemical durability of parenteral glass packaging is the hydrolytic resistance test in which the vial is filled to 90% of its brimful volume as described, for example, in USP <660>. However, an increasing number of innovative drugs are filled significantly below the nominal volume of the vial. As a consequence, the determined hydrolytic resistance is not representative of the concentrations of leached "glass" elements for low fill volumes. This is attributable to two main factors: Firstly, an increasing ratio of the wetted surface to volume and secondly an increased leaching tendency typically observed with borosilicate glass of the wall near bottom area, especially when standard manufacturing technology is applied.The extent of both contributing effects has been analyzed by determining the amounts of the representative leached "glass" elements, boron, sodium, and silicon, after vial storage for 24 weeks at 40°C with different fill volumes (0.5, 1.0, and 2.0 mL). The vials which have been investigated in this study have a nominal fill volume of 2 mL, were made from Type I class B borosilicate glass (Fiolax®) and from aluminosilicate glass and were filled with either purified water or a 15% KCl solution.The standard conversion process for tubing into vials was used for Fiolax vials (standard quality vials) and for aluminosilicate vials. In addition, an optimized conversion process (delamination controlled technology) was used to create low-fill quality Fiolax vials. The vial quality obtained from the two different converting technologies greatly influenced the concentrations of leached "glass" elements measured, especially when low fill volumes were used. Borosilicate glass containers, because of their chemical inertness, excellent barrier properties, high transparency, and mechanical stability, have been successfully used for decades to package parenteral drug formulations. Nevertheless, Type I glass can be altered over a period of time when in contact with the drug formulation. The result of this interaction is even more pronounced for some new innovative drugs that are delivered to the patient in small dosages significantly below the nominal storage capacity of the glass vials. When the fill volume of the vials is reduced, the contribution of the bottom area to the wetted surface increases, resulting in a higher surface-to-volume ratio. Therefore, the concentrations of leached elements will be increased and this can cause problems for sensitive medical products. This effect is not usually observed with the standard test procedures described in the pharmacopeia because the vials are filled with a high volume to 90% brimful capacity (e.g., as described in USP <660>). In this study, the leachable behaviors of vials made of borosilicate and aluminosilicate glass were evaluated by using medium and low fill volumes with storage for 24 weeks at 40°C. The standard conversion process to manufacture a vial from glass tubing introduces volatile "glass" elements into the vial wall near the bottom area. This mechanism has been described and supported by time-of-flight secondary ion mass spectrometry (TOF-SIMS) measurements of the inner vial surface as reported by Rupertus et al. The diffusion mechanism of volatile components will increase the leaching propensity of the vial, especially for low fill volumes. However, innovative manufacturing techniques are able to avoid the diffusion of volatile elements into the wall near the bottom area. This is achieved by a specific process setup in combination with a suitable monitoring test during vial production, which gives a quantitative measure of the leaching tendency of the wall near the bottom area. Borosilicate glass vials manufactured with this setup (low-fill quality vials) showed a drastic reduction in leachables, especially with low fill volumes. Vials composed of a boron-free glass showed no advantages in terms of leaching behavior when compared with borosilicate glass vials in general.
用于测量注射用玻璃包装化学耐久性的药典方法是耐水解性试验,即按照例如美国药典<660>中所述,将小瓶填充至其满容量的90%。然而,越来越多的创新药物填充量显著低于小瓶的标称体积。因此,所测定的耐水解性不能代表低填充量下浸出的“玻璃”元素的浓度。这主要归因于两个因素:首先,湿润表面积与体积的比例增加;其次,通常在底部附近区域的硼硅酸盐玻璃壁上观察到浸出趋势增加,特别是在应用标准制造技术时。通过在40°C下用不同填充量(0.5、1.0和2.0 mL)储存小瓶24周后,测定代表性浸出“玻璃”元素硼、钠和硅的含量,分析了这两种影响因素的程度。本研究中所研究的小瓶标称填充量为2 mL,由I类B型硼硅酸盐玻璃(Fiolax®)和铝硅酸盐玻璃制成,并填充有纯化水或15%的氯化钾溶液。Fiolax小瓶(标准质量小瓶)和铝硅酸盐小瓶采用了将管材转换为小瓶的标准工艺。此外,还采用了优化的转换工艺(分层控制技术)来制造低填充量质量的Fiolax小瓶。从两种不同转换技术获得的小瓶质量极大地影响了所测定的浸出“玻璃”元素的浓度,特别是在使用低填充量时。硼硅酸盐玻璃容器由于其化学惰性、优异的阻隔性能、高透明度和机械稳定性,几十年来一直成功用于包装注射用药物制剂。然而,I类玻璃在与药物制剂接触一段时间后可能会发生变化。对于一些以小剂量给药给患者且显著低于玻璃小瓶标称储存容量的新型创新药物,这种相互作用的结果更为明显。当小瓶的填充量减少时,底部区域对湿润表面的贡献增加,导致表面积与体积比更高。因此,浸出元素的浓度会增加,这可能会给敏感的医疗产品带来问题。药典中描述的标准测试程序通常不会观察到这种影响,因为小瓶填充至满容量的90%(例如,如美国药典<660>中所述)。在本研究中,通过使用中等和低填充量,并在40°C下储存24周,评估了硼硅酸盐和铝硅酸盐玻璃制成的小瓶的可浸出行为。由玻璃管材制造小瓶的标准工艺会将挥发性“玻璃”元素引入底部附近区域的瓶壁中。如Rupertus等人报道的,飞行时间二次离子质谱(TOF-SIMS)对小瓶内表面的测量描述并支持了这种机制。挥发性成分的扩散机制会增加小瓶的浸出倾向,特别是对于低填充量。然而,创新的制造技术能够避免挥发性元素扩散到底部附近区域的瓶壁中。这是通过在小瓶生产过程中结合特定的工艺设置和合适的监测测试来实现的,该测试可以定量测量底部附近区域瓶壁的浸出倾向。采用这种设置制造的硼硅酸盐玻璃小瓶(低填充量质量小瓶)显示出可浸出物的大幅减少,特别是在低填充量时。与硼硅酸盐玻璃小瓶相比,由无硼玻璃制成的小瓶在浸出行为方面一般没有优势。